# Potential of herbal formulas and bioactive metabolites in treating atherosclerosis: targeted modulation of macrophage polarization

**Authors:** Shixin Liu, Jinpeng Jing, Yunsha Zhang, Junchao Sun, Chaojun Zhu

PMC · DOI: 10.3389/fphar.2025.1631274 · 2025-11-06

## TL;DR

This paper reviews how herbal formulas and bioactive compounds from traditional Chinese medicine can help treat atherosclerosis by influencing macrophage behavior.

## Contribution

The paper uniquely emphasizes traditional Chinese medicine as a multi-target regulator of macrophage plasticity in atherosclerosis.

## Key findings

- Bioactive metabolites like ginsenosides, berberine, curcumin, and tanshinone IIA promote M2 macrophage polarization and suppress M1 phenotypes.
- Herbal formulas such as Bu Yang Huan Wu Decoction and Zhuyu Pill show efficacy in modulating macrophage polarization to mitigate atherosclerosis.
- Targeted modulation of macrophage polarization through specific signaling pathways is a promising therapeutic strategy.

## Abstract

Macrophage polarization plays a pivotal role in the pathogenesis and plaque stability of atherosclerosis (AS). In response to microenvironmental cues, macrophages differentiate into pro-inflammatory M1 or anti-inflammatory M2 phenotypes, which respectively exacerbate or mitigate inflammatory responses and influence plaque progression. Emerging evidence highlights the therapeutic potential of targeting macrophage polarization through signaling pathways such as Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB), peroxisome proliferator-activated receptor γ (PPAR-γ), Janus kinase (JAK)-signal transducer and activator of transcription (STAT), phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, and mitogen-activated protein kinase (MAPK) pathway. Bioactive metabolites derived from traditional Chinese medicine (TCM)—including ginsenosides (e.g., Rb1, Rg3), berberine (BBR), curcumin (CUR), and tanshinone IIA (Tan IIA)—as well as herbal formulas like Bu Yang Huan Wu Decoction (BYHW) and Zhuyu Pill (ZYP), have demonstrated efficacy in promoting M2 polarization and suppressing M1 phenotypes, thereby attenuating AS. This review critically synthesizes the current body of evidence, with a primary focus on preclinical studies (in vitro and in vivo), which comprehensively synthesizes evidence on the targeted modulation of AS-associated macrophage polarization by bioactive metabolites and herbal formulas, with a unique emphasis on the role of TCM as a multi-target regulator of macrophage plasticity. This approach provides novel perspectives for the prevention and treatment of AS.

## Linked entities

- **Proteins:** MPK1 (mitogen-activated protein kinase 1)
- **Chemicals:** ginsenosides (PubChem CID 3086007), Rb1 (PubChem CID 736494), Rg3 (PubChem CID 169408342), berberine (PubChem CID 2353), curcumin (PubChem CID 969516), tanshinone IIA (PubChem CID 164676)
- **Diseases:** atherosclerosis (MONDO:0005311)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** AS (MESH:D050197), inflammatory (MESH:D007249)
- **Chemicals:** BBR (MESH:D001599), Rb1, Rg3 (-), Tan IIA (MESH:C021751), ginsenosides (MESH:D036145), CUR (MESH:D003474)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12631451/full.md

---
Source: https://tomesphere.com/paper/PMC12631451